JP Morgan Chase’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
Other funds holding NVAX
SCM
S
JP Morgan Chase's NVAX Position: Q2 2026 in Review
JP Morgan Chase increased its Novavax (NVAX) stake by 1.7% in Q2 2026, buying an estimated $11.5K and bringing the position to 76,487 shares worth $716K. The position accounts for ﹤0.01% of the portfolio, ranked #4884.
JP Morgan Chase first reported a position in NVAX in Q2 2013 and has held it in 51 quarters since. The position peaked at $83.8M in Q1 2021. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.
- JP Morgan Chase held 76,487 shares of Novavax worth $716K as of Q2 2026.
- JP Morgan Chase bought 1,287 Novavax shares in Q2 2026, an estimated $11.5K.
- Novavax made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4884 holding.
- JP Morgan Chase first reported a position in Novavax in Q2 2013 and has held it in 51 quarters since.
- JP Morgan Chase's Novavax position peaked at $83.8M in Q1 2021.
- 268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.